- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
FDA Approves Smart Programmer for the InterStim System
Medtronic (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive urinary retention. As quoted in the press release: The new smart programmer streamlines multiple devices into …
Medtronic (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive urinary retention.
As quoted in the press release:
The new smart programmer streamlines multiple devices into a single, intuitive, touch screen Samsung mobile device and enables clinicians to personalize each patient’s care and allows patients to manage their therapy simply and discreetly. OAB and FI are treatable, extremely common and embarrassing conditions. More than 37 million adults in the United States – almost one in six – suffer from OAB and nearly 20 million Americans – about one in 12 – have bowel incontinence.1-4
“In addition to simplified programming and ongoing management of InterStim therapy, the smart programmer is discreet, which is meaningful to patients because OAB can greatly impact confidence, intimacy and activities,” said Steven Siegel, M.D., Metro Urology Centers for Female Urology and Continence Care, Minneapolis, Minn. “It takes courage to seek treatment and many struggle to find long-term relief. My goal is to address OAB symptoms and help restore my patients’ quality of life, and I’m pleased to have a tool like the InterStim smart programmer for patients who may benefit from neuromodulation.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â